Reuters logo
BRIEF-Impact Biomedicines receives $22.5 mln from Medicxi through a series A financing​
October 13, 2017 / 12:54 PM / 2 months ago

BRIEF-Impact Biomedicines receives $22.5 mln from Medicxi through a series A financing​

Oct 13 (Reuters) -

* Impact Biomedicines says it has received $22.5 million from Medicxi through a series A financing​

* Impact Biomedicines says the ‍U.S. FDA has removed clinical hold placed on fedratinib​

* Impact Biomedicines says fedratinib​ ‍is being developed initially for treatment of myelofibrosis and polycythemia vera Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below